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Candidemia in acute leukemia patients
Abstract Fungal infections are an
important cause of morbidity and
mortality in patients with acute
leukemia (AL). Candidemia, once
rare, is now a common nosocomial
infection because of the intensity
of chemotherapy, prolonged neu-
tropenia, administration of broad-
spectrum antibiotics and use of
central venous catheters (CVC).
We retrospectively identified pa-
tients treated for AL from 6/86 to
6/95 who also had candidemia. We
describe 28 patients (incidence
6.3%) with a median age of 39
years, 24 of whom were on remis-
sion induction and 4 on postremis-
sion chemotherapy. All patients
had CVC and empiric antimicro-
bial therapy, 4 had been given pro-
phylactic antifungal drugs, and 2
had parenteral nutrition. Neutrope-
nia was profound (median leuko-
cyte nadir 200/ml, median duration
19 days). Candida was isolated in
blood cultures 10 days (median)
after the start of neutropenia. The
clinical presentation included fever
(100%), respiratory symptoms
(71.4%), skin lesions (39.2%) and
septic shock (17.8%). Amphoteri-
cin B was given to 17 patients and
liposomal amphotericin to 5 pa-
tients. Infection resolved in 18 pa-
tients (64.2%), 10 of whom were in
complete remission. Mortality from
candidemia was 17.8% (5/28). In
conclusion, fungal infections are re-
sponsible for death in a significant
number of patients. In our series
treatment success was related to its
rapid onset and to the recovery of
neutropenia.
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Fungal infection is an important cause of morbidity and
mortality in immunocompromised patients. Its inci-
dence has risen steadily and considerably in the last de-
cades in AL patients as a result of the intensity of che-
motherapy, prolonged neutropenia, cellular immune
deficiency, rupture of natural barriers, and better sup-
portive care (use of CVC, broad-spectrum antibiotics
and parenteral nutrition). These factors favor the oc-
currence of candidemia among immunocompromised
hosts in particular. Its incidence is 4–12% [1, 4]. There
is a growing concern about its high mortality rate (46–
75%) [9, 15]. Antifungal prophylaxis, by diminishing
the burden of Candida in the intestinal flora, may lower
the incidence of candidemia and disseminated candidia-
sis [17]. On the other hand, triazoles may favor the
emergence of certain species, such as C. krusei and C.
glabrata [2, 10, 11], without any real reduction in the
incidence of candidemia [10]. Preliminary data on the
usefulness of colony-stimulating factors in prophylaxis
or as an adjuvant to therapy [17] need to be confirmed.
Optimal management of candidemia is still controver-
sial, but amphotericin B remains the preparation of
choice for neutropenic patients, although its toxicity
limits its generalized use [12]. Unfortunately, there are
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few comparative studies examining lipid formulations
of amphotericin B and with flucytosine. Retrospective
analyses suggest some advantage of the association
with flucytosine, but more adverse effects and higher
costs [11]. Resolution of the neutropenia and complete
remission of the hematologic malignancies are asso-
ciated with a favorable outcome [17], although this is
not accepted by all authors [8]. We report the inci-
dence, risk factors, clinical features, therapy and out-
come of candidemia in AL patients at our institution.
Patients and methods
We retrospectively reviewed all files from patients with AL
treated from April 1986 to April 1995 and selected those with
candidemia. Candidemia was defined as the presence of at least
one positive blood culture for Candida. Yeasts were identified by
means of the API (ID32C) System. The presence of the following
predisposing factors for candidemia was recorded for each case:
duration and depth of leukopenia, defined as leukocytes ‹1000/ml;
previous administration of broad-spectrum antibiotics; parenteral
nutrition; and indwelling CVC. Clinical manifestations, type and
dosage of antifungal drugs used, and adverse effects of treatment
were evaluated. Outcome was recorded as cure, for complete clin-
ical resolution with subsequent negative blood cultures, or as fail-
ure, for any other outcome, including visceral localizations.
Chronic disseminated candidiasis was diagnosed in patients with
persistent fever after neutrophil recovery, abdominal symptoms,
elevated serum alkaline phosphatase, and demonstration on CT
scan of multiple hepatosplenic microabscesses, with or without
histopathologic documentation.
Results
Of the 442 AL patients, 28 had candidemia (incidence
6.3%); 15 were male and 13 female, median age was 39
years (range 13 to 72), and AL was nonlymphoblastic
in 19 and lymphoblastic in 9. Patients were nursed on
an open ward; 24 were on a remission induction course
(their first course in 11 cases) and the remaining 4 on
postremission therapy. Treatment included high-dose
cytarabine in 12 cases. Antifungal prophylaxis was not
routinely used. Among the known predisposing factors
for candidemia, all patients had long-lasting profound
neutropenia, had indwelling CVC, and had been given
broad-spectrum antibiotics, but only 2 had parenteral
nutrition (Table 1).
Respiratory tract symptoms predominated in clinical
presentation (Table 2), although only 6 patients had
positive findings in the chest roentgenogram, consisting
of diffuse bilateral interstitial infiltrates, homogeneous
consolidations, and pleural effusions. The relationship
of these findings to candidemia could not be definitely
established by tissue biopsy, because of thrombocyto-
penia, and other methods (CT scan in 4 patients, bron-
choalveolar lavage in 2) were inconclusive; no concur-
rent infections were diagnosed.
Candida was isolated from the blood between days 4
and 30 of the chemotherapy course, after a median of
10 days with leukocytes ‹1000/ml. Median number of
positive blood cultures was 2 (range 1–7) per patient. C.
parapsilosis was isolated in 5 cases, C. albicans in 3, C.
tropicalis in 3, C. krusei in 3 and in the remaining 14 the
Candida spp. were not further characterized.
Amphotericin B (0.5–1.5 mg/kg per day) was given
to 17 patients, liposomal amphotericin (2.5–4 mg/kg per
day) to 5 patients (1 of these with added flucytosine),
and itraconazole to 1 patient. No antifungal therapy
was given to 5 patients; this was due to spontaneous
cure in 2 cases, both with AL in complete remission,
and to death from Candida sepsis before candidemia
was recognized in 3 cases. Side effects of amphotericin
B were rigors and fever despite premedication in 13 pa-
tients, hypokalemia in 14, and a rise in serum creatinine
(WHO grade ‹3) in 9.
The outcome was cure in 18 of 28 patients (64.2%),
10 of whom were in complete remission of AL. Cure
was achieved with liposomal amphotericin in 4 patients
and with amphotericin B in 14. The remaining 10 cases
were classified as failures :5 (17.8%) died from Candida
sepsis and 5 progressed to chronic disseminated candid-
iasis. The CVC was removed from 10 patients (4 of
them demonstrating line colonization by the same Can-
dida species as was found in the blood) :7 of these were
cured and in 3 the treatment failed.
There was no significant difference between cure
and failure cases in the dose of amphotericin (mean
1.07 mg/kg per day versus 1.2) or in the mean duration
of fever before treatment with amphotericin was begun
(11 versus 9 days).
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Discussion
The candidemia rate of 6.3% found in our AL patients
is similar to rates published in the literature [1, 4, 16].
The growing incidence of non-albicans species has re-
cently been stressed and reaches 46% of fungal infec-
tions in some studies [19]; this change is probably re-
lated to the prophylactic use of triazoles. In our series,
one third of the cases in which the species of Candida
was identified were affected by C. parapsilosis, which
has been associated with exogenous contamination
from CVC and with parenteral nutrition [3, 13, 14, 18].
As for other predisposing factors, all our patients had
been given broad-spectrum antibiotics and aggressive
chemotherapy (nearly half with high-dose cytarabine),
which results in prolonged neutropenia and rupture of
mucosal barriers.
The mortality rate of candidemia is high (46–75%)
[7, 9, 15] unless neutropenia resolves. Antifungal pro-
phylaxis was unable to reduce its incidence or mortality
rate in neutropenic patients in randomized trials [20],
except in the case of bone marrow transplantation [5,
6]. Our patients did not have routine prophylaxis, and
most were treated with amphotericin B, which remains
the drug of choice in neutropenic patients. The removal
of CVC in candidemia is controversial, except in the
case of tunnel infection or persistence of positive blood
cultures after appropriate therapy [1, 14]. Only 7 of our
18 cured patients had their CVC removed, indicating
that response is possible without removal. The excel-
lent cure rate (64%) found in our series probably stems
from early empirical treatment with amphotericin B as
much as from resolution of neutropenia and remission
of the underlying leukemia in the majority of patients.
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